Pituitary adenylate cyclase-activating peptide (PACAP; 1-38 and 1-27) and vasoactive intestinal peptide (VIP) are related neuropeptides of the secretin/glucagon family. Overlapping signaling through G-protein-coupled receptors mediates their vasomotor activity. We previously showed that PACAP deficiency (PACAP-KO) shifts the mechanisms of vascular response and maintains arterial relaxation through the VIP backup mechanism and (mainly) its VPAC1R, but their age-dependent modulation is still unknown. We hypothesized that backup mechanisms exist, which maintain the vasomotor activity of these peptides also in older age. Thus, we investigated the effects of exogenous VIP and PACAP peptides in isolated carotid arteries of 2- and 15-month-old wild-type (WT) and PACAP-KO mice. All peptides induced relaxation in the arteries of young WT mice, whereas in young PACAP-KO mice PACAP1-27 and VIP, but not PACAP1-38, induced relaxation. Unlike VIP, PACAP-induced vasomotor responses were reduced in aging WT mice. However, in the arteries of aging PACAP-KO mice, PACAP1-27- and VIP-induced responses were reduced, but PACAP1-38 showed a greater vasomotor response compared to that of young PACAP-KO animals. There were no significant differences between the vasomotor responses of aging WT and PACAP-KO mice. Our data suggest that, in the absence of PACAP both in young and old ages, the vascular response is mediated through backup mechanisms, most likely VIP, maintaining proper vascular relaxation in aging-induced PACAP insufficiency.

1.
Vaudry D, Falluel-Morel A, Bourgault S, et al: Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 2009;61:283-357.
2.
Segre GV, Goldring SR: Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family. Trends Endocrinol Metab 1993;4:309-314.
3.
Fahrenkrug J, Hannibal J, Tams J, Georg B: Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves. J Cereb Blood Flow Metab 2000;20:1205-1214.
4.
Nandha KA, Benito-Orfila MA, Smith DM, Ghatei MA, Bloom SR: Action of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on the rat vascular system: effects on blood pressure and receptor binding. J Endocrinol 1991;129:69-73.
5.
Ross-Ascuitto NT, Ascuitto RJ, Ramage D, Kydon DW, Coy DH, Kadowitz PJ: Pituitary adenylate cyclase activating polypeptide: a neuropeptide with potent inotropic and coronary vasodilatory effects in neonatal pig hearts. Pediatr Res 1993;34:323-328.
6.
Naruse S, Suzuki T, Ozaki T, Nokihara K: Vasodilator effect of pituitary adenylate cyclase activating polypeptide (PACAP) on femoral blood flow in dogs. Peptides 1993;14:505-510.
7.
Ivic I, Fulop BD, Juhasz T, et al: Backup mechanisms maintain PACAP/VIP-induced arterial relaxations in pituitary adenylate cyclase-activating polypeptide-deficient mice. J Vasc Res 2017;54:180-192.
8.
Markovics A, Kormos V, Gaszner B, et al: Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice. Neurobiol Dis 2012;45:633-644.
9.
Anzai M, Suzuki Y, Takayasu M, et al: Vasorelaxant effect of PACAP-27 on canine cerebral arteries and rat intracerebral arterioles. Eur J Pharmacol 1995;285:173-179.
10.
Erdling A, Sheykhzade M, Maddahi A, Bari F, Edvinsson L: VIP/PACAP receptors in cerebral arteries of rat: characterization, localization and relation to intracellular calcium. Neuropeptides 2013;47:85-92.
11.
Vamos Z, Ivic I, Cseplo P, et al: Pituitary adenylate cyclase-activating polypeptide (PACAP) induces relaxations of peripheral and cerebral arteries, which are differentially impaired by aging. J Mol Neurosci 2014;54:535-542.
12.
Wilson AJ, Warren JB: Adenylate cyclase-mediated vascular responses of rabbit aorta, mesenteric artery and skin microcirculation. Br J Pharmacol 1993;110:633-638.
13.
Chan KY, Baun M, de Vries R, et al: Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery. Cephalalgia 2011;31:181-189.
14.
Reglodi D, Kiss P, Szabadfi K, et al: PACAP is an endogenous protective factor - insights from PACAP-deficient mice. J Mol Neurosci 2012;48:482-492.
15.
Hashimoto H, Shintani N, Tanaka K, et al: Altered psychomotor behaviors in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). Proc Natl Acad Sci USA 2001;98:13355-13360.
16.
Tripathy D, Sanchez A, Yin X, Martinez J, Grammas P: Age-related decrease in cerebrovascular-derived neuroprotective proteins: effect of acetaminophen. Microvasc Res 2012;84:278-285.
17.
Banki E, Sosnowska D, Tucsek Z, et al: Age-related decline of autocrine pituitary adenylate cyclase-activating polypeptide impairs angiogenic capacity of rat cerebromicrovascular endothelial cells. J Gerontol A Biol Sci Med Sci 2015;70:665-674.
18.
Reglodi D, Kiss P, Lubics A, Tamas A: Review on the protective effects of PACAP in models of neurodegenerative diseases in vitro and in vivo. Curr Pharm Des 2011;17:962-972.
19.
Mulvany MJ, Halpern W: Contractile properties of small arterial resistance vessels in spontaneously hypertensive and normotensive rats. Circ Res 1977;41:19-26.
20.
Ivic I, Vamos Z, Cseplo P, Koller A: From newborn to senescence morphological and functional remodeling leads to increased contractile capacity of arteries. J Gerontol A Biol Sci Med Sci 2017;72:481-488.
21.
Jozsa R, Hollosy T, Tamas A, Toth G, Lengvari I, Reglodi D: Pituitary adenylate cyclase activating polypeptide plays a role in olfactory memory formation in chicken. Peptides 2005;26:2344-2350.
22.
Tamas A, Reglodi D, Farkas O, et al: Effect of PACAP in central and peripheral nerve injuries. Int J Mol Sci 2012;13:8430-8448.
23.
Huang M, Shirahase H, Rorstad OP: Comparative study of vascular relaxation and receptor binding by PACAP and VIP. Peptides 1993;14:755-762.
24.
Cheng DY, McMahon TJ, Dewitt BJ, et al: Comparison of responses to pituitary adenylate cyclase activating peptides 38 and 27 in the pulmonary vascular bed of the cat. Eur J Pharmacol 1993;243:79-82.
25.
Baun M, Hay-Schmidt A, Edvinsson L, Olesen J, Jansen-Olesen I: Pharmacological characterization and expression of VIP and PACAP receptors in isolated cranial arteries of the rat. Eur J Pharmacol 2011;670:186-194.
26.
Lee JC, Cho YJ, Kim J, et al: Region-specific changes in the immunoreactivity of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC2, and PAC1 receptor) in the aged rat brains. Brain Res 2010;1351:32-40.
27.
Joo KM, Chung YH, Lim HC, Lee KH, Cha CI: Reduced immunoreactivities of a vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptor (VPAC1 receptor) in the cerebral cortex, hippocampal region, and amygdala of aged rats. Brain Res 2005;1064:166-172.
28.
Ogawa T, Nakamachi T, Ohtaki H, et al: Monoaminergic neuronal development is not affected in PACAP-gene-deficient mice. Regul Pept 2005;126:103-108.
29.
Girard BA, Lelievre V, Braas KM, et al: Noncompensation in peptide/receptor gene expression and distinct behavioral phenotypes in VIP- and PACAP-deficient mice. J Neurochem 2006;99:499-513.
30.
Takuma K, Maeda Y, Ago Y, et al: An enriched environment ameliorates memory impairments in PACAP-deficient mice. Behav Brain Res 2014;272:269-278.
31.
Pirger Z, Naskar S, Laszlo Z, Kemenes G, Reglodi D, Kemenes I: Reversal of age-related learning deficiency by the vertebrate PACAP and IGF-1 in a novel invertebrate model of aging: the pond snail (Lymnaea stagnalis). J Gerontol A Biol Sci Med Sci 2014;69:1331-1338.
32.
Ungvari Z, Kaley G, de Cabo R, Sonntag WE, Csiszar A: Mechanisms of vascular aging: new perspectives. J Gerontol A Biol Sci Med Sci 2010;65:1028-1041.
33.
Tuka B, Szabo N, Toth E, et al: Release of PACAP-38 in episodic cluster headache patients - an exploratory study. J Headache Pain 2016;17:69.
34.
Dorner GT, Wolzt M, Eichler HG, Schmetterer L: Effect of pituitary adenylate cyclase activating polypeptide 1-27 on ocular, cerebral and skin blood flow in humans. Naunyn Schmiedebergs Arch Pharmacol 1998;358:657-662.
35.
Hedlund P, Alm P, Ekstrom P, et al: Pituitary adenylate cyclase-activating polypeptide, helospectin, and vasoactive intestinal polypeptide in human corpus cavernosum. Br J Pharmacol 1995;116:2258-2266.
36.
Kovacs-Valasek A, Szabadfi K, Denes V, et al: Accelerated retinal aging in PACAP knock-out mice. Neuroscience 2017;348:1-10.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.